News | January 26, 2022
Torrent Pharmaceuticals consolidated PAT at Rs 249 cr
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Go-ahead for pivotal clinical trial which is expected to commence by March
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Biocon has reported consolidated financial results for the period ended December 31, 2021
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Subscribe To Our Newsletter & Stay Updated
